Skip to main content
Premium Trial:

Request an Annual Quote

Lion Posts Revenue Drop, Ballooning Losses

SAN FRANCISCO, Aug. 7 - Lion Bioscience today reported a decrease in first-quarter revenue on top of expanding net losses.


Total revenue in the quarter ended June 30 decreased to €7.5 million, or roughly $7.3 million, from €8.9 million in the year-ago period, Lion said.


Net loss for the quarter ballooned to €19.2 million, or €.97 per share, from €11.2 million, or €.60 per share, one year ago. The company attributed increased losses to costs integrating NetGenics, acquired in January, as well as a year-over-year drop in revenue.


The company did register an increase in revenue from software licenses, CEO Friedrich von Bohlen said in a statement.


R&D costs increased to €11.6 million for the quarter ended June 30 compared to €10.1 million for the year-ago period.


Lion said it had €37.4 million cash and cash equivalents as of June 30. The company had €66.4 million in short-term marketable securities at the end of the first quarter compared to €104.8 million as of March 31, 2002.


Click here for more information.

The Scan

Harvard Team Report One-Time Base Editing Treatment for Motor Neuron Disease in Mice

A base-editing approach restored SMN levels and improved motor function in a mouse model of spinal muscular atrophy, a new Science paper reports.

International Team Examines History of North American Horses

Genetic and other analyses presented in Science find that horses spread to the northern Rockies and Great Plains by the first half of the 17th century.

New Study Examines Genetic Dominance Within UK Biobank

Researchers analyze instances of genetic dominance within UK Biobank data, as they report in Science.

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.